Research Detailing Advantages of Rutherrin® PhotoDynamic Therapy in deadly brain cancer, GlioBlastoma Multiforme (“GBM”) to be Published in the Journal of Neuro-Oncology Advances Toronto, Ontario – June 25, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that a scientific paper pertaining to the Company’s Rutherrin® based Photo Dynamic Therapy (“PDT”) has been peer reviewed and selected for publication in Neuro-Oncology Advances (“NOA”). Publication in NOA of Theralase’s latest pre-clinical research of Rutherrin® PDT treatment targeting GlioBlastoma Multiforme (“GBM”), assisted through a collaboration with researchers at University Health Network’s (“UHN”) Princess Margaret Cancer Centre, allows many specialists in the field of neuro-oncology the opportunity to learn about Theralase’s advances in this field. As an … Read More

Toronto, Ontario – April 17, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released the audited financial statements for the year ended December 31, 2018. Total revenue for the year ended December 31, 2018 decreased to 1,734,072 from 2,342,508 in 2017, a 26% decrease. In Canada, revenue decreased 38% to $1,205,312 from $1,942,010. In the US, revenue increased 16% to $304,785 from $261,833 and international revenue increased 62% to $223,975 from $138,665. The decrease in total revenue in 2018 is primarily due to the restructuring of the sales and marketing departments resulting in the termination of certain sales and marketing personnel and decreased spending in advertising. Cost of sales for the year ended December 31, … Read More

Toronto, Ontario – June 18, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers filed its amended and restated condensed interim consolidated financial statements and Management Discussion and Analysis (“MD&A”) as at and for the three-months ended March 31, 2019. Management of the Company has determined that the property lease for the Company’s premises and office equipment was not properly recorded under International Financial Reporting Standards (“IFRS”) 16 Leases, which came into effect on January 1, 2019 and provides guidance on how to recognize, measure, present and disclose leases.  As a result, the Company amended and restated the condensed interim consolidated financial statements and MD&A for 1Q2019.  The impact of the correction is as follows: Decrease in … Read More

Toronto, Ontario – May 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its 1Q2019 financial statements. Total revenue for the three-month period ended March 31, 2019, decreased to $121,179 from $441,193 for the same period in 2018, a 73% decrease. In Canada, revenue decreased 61% to $116,104 from $297,061. In the US, revenue decreased 94% to $5,075 from $90,354 and international revenue decreased 100% from $53,778 to $Nil during the three-month period ended March 31, 2019. The decrease in total revenue in 2019 is primarily due to the restructuring of the sales and marketing departments resulting in the termination of certain sales and marketing personnel in 2018 and the hiring of new marketing … Read More

Toronto, Ontario – May 20, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Company has been granted a Notice of Acceptance by the Chinese patent office for PDCs. The patent entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use” advances Theralase’s intellectual property portfolio internationally and permits the Company to expand Theralase’s advanced PhotoDynamic Therapy (“PDT”) technology in the Chinese market, subject to Chinese regulatory approvals. The patent encompasses an extensive library of PDCs, including Theralase’s lead PDC, TLD-1433, recently Health Canada Clinical Trial Authorization (“CTA”) and Investigational Testing Authorization (“ITA”) approved to be evaluated in a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study. China is the most … Read More

Toronto, Ontario – May 13, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers announced that Theralase recently met with its Medical and Scientific Advisory Board (“MSAB”), as well as potential Principal Investigators (“PIs”), who are interested in participating in the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“ACT-NMIBC”). The meeting focused primarily on the presentation of the clinical endpoints achieved in the successfully completed Phase Ib NMIBC clinical study, as well as a discussion on the design and FDA regulatory requirements pertaining to the ACT-NMIBC. The FDA provided guidance to the industry in February 2018, entitled, “BCG-Unresponsive Nonmuscle Invasive Bladder Cancer:  Developing Drugs and Biologics for Treatment  Guidance for Industry”. In the guidance, the … Read More

Toronto, Ontario – May 7, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Chinese Patent Office has Issued a Notice of Acceptance for a patent application concerning Multiwavelength PhotoDynamic Therapy (“PDT”) to the Company. The patent entitled, “Apparatus and Method for Multiwavelength PhotoDynamic Therapy” validates the proprietary position of the Company and opens opportunities for the application of Theralase’s PDT technology in an international market. Kipton P. Lade, CEO – Device Division, Theralase stated, “Theralase continues to advance it’s Anti-Cancer Therapy (“ACT”) through optimization of the technology and protecting those advancements through a comprehensive intellectual property strategy. This new multiwavelength laser system is the latest addition to our technology platform, … Read More

Toronto, Ontario – May 6, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the Company’s Anti-Cancer Therapy (“ACT”) for Non-Muscle Invasive Bladder Cancer (“NMIBC”) in a Phase Ib clinical study, was selected for presentation at the American Urological Association (“AUA”) conference, held in Chicago, Illinois on May 3rd to May 6th, 2019. The AUA is a premier urologic association, that provides invaluable support to the urologic community, with a mission to promote the highest standards of urological clinical care through education, research and the formulation of health care policy. The annual AUA conference brings together medical professionals and researchers from around the globe to discuss and present the latest advances in urological … Read More

Toronto, Ontario – April 25, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that the University Health Network Research Ethics Board (“UHN-REB”) has approved the commencement of a Phase II clinical study to evaluate Theralase’s Anti-Cancer Treatment (“ACT”) titled, “Patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”), who present with Carcinoma In-Situ (“CIS”), who are considered Bacillus Calmette Guérin (“BCG”) – Unresponsive or are intolerant to BCG Therapy (“ACT-NMIBC”)”. The ACT-NMIBC study has been designed in compliance with FDA industry guidelines issued February, 2018 for BCG-unresponsive NMIBC. The study will utilize the Therapeutic Dose (0.70 mg/cm) of TLD-1433 and will focus on the treatment of approximately 100 to 125 BCG-unresponsive NMIBC patients, with CIS, in approximately … Read More

Nine Scientific Papers Detailing the Latest Scientific Research of Theralase®’s Anti-Cancer Technology (“ACT”) Platform have been Peer Reviewed and will be Presented at the International Photodynamic Association World Congress Toronto, Ontario – April 15, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce nine scientific papers pertaining to the Company’s Anti-Cancer Technology (“ACT”) Platform and Rutherrin® based Photo Dynamic Therapy (“PDT”) have been peer reviewed and selected for presentation at the 17th Annual International Photodynamic Association (“IPA”) World Congress, to be held in Cambridge, Massachusetts, USA from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PDT and PhotoDiagnosis (“PD”) since 1986. Every … Read More